Compare Novo Nordisk A/S (NVO) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Visa Inc — how do they compare? Novo Nordisk A/S trades at $45.76 (market cap $207.85B), while Visa Inc trades at $361.98 (market cap $671.74B). The key difference: Visa Inc is far larger — about 3.2× Novo Nordisk A/S's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| NVO | V | |
|---|---|---|
Market Cap | $207.85B | $671.74B |
Sector | Health | Financials |
52-Week High | $63.98 | $370.47 |
52-Week Low | $35.29 | $295.52 |
Enterprise Value | $222.55B | $682.32B |
Dividend Yield | 3.81% | 0.74% |
Volume | — | 10,431,336 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Visa (V) trades at $361.32, down 0.33% on the day, with a bearish technical signal but strong fundamentals including a 50.78% net income margin and consistent earnings beats. Recent news highlights AI-driven commerce initiatives and stablecoin partnerships, positioning the company for future growth. The stock is near its pivot point of $361, with support at $359 and resistance at $364.
The outlook remains positive with an 85% analyst buy rating and a $426.31 consensus price target, implying 18% upside. Risks include fintech competition and regulatory pressures, but Visa's robust cash flow and high profitability support long-term value. The next earnings report on April 28, 2026, will be a key catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
